ATLX-1088

ATLX-1088 is a potential first-in-class human antibody developed by Alchemab Therapeutics for the treatment of Alzheimer's disease. It targets CD33, a cell surface protein that plays an inhibitory role in microglial function within the brain. Elevated expression of CD33 is associated with advanced cognitive decline and increased amyloid-beta plaque burden in Alzheimer's disease, as it suppresses the phagocytic activity of microglia—cells responsible for clearing toxic proteins and maintaining neural health. ATLX-1088 acts as a CD33 antagonist, binding to the sialoglycan epitope on CD33 and likely competing for its ligand binding site. This non-internalizing antibody has demonstrated improved pharmacokinetics and increases phagocytosis of amyloid-beta by microglia in preclinical models, potentially restoring healthy brain cell function and reducing neuroinflammation. The drug was discovered through analysis of antibodies from individuals resilient to Alzheimer’s disease[1][3][4][6].